Close Menu

White House

Move It Along

In a speech to Congress, President Donald Trump called the drug approval process at FDA "slow and burdensome."

A floated budget plan could see non-military discretionary spending in the US — which includes science agency funding — fall, the New York Times reports.

Researchers rally near the American Association for the Advancement of Science annual meeting in Boston.

A candidate to be President Donald Trump's science advisor supports limiting federal researchers' ability to discuss their findings, the Guardian reports.

Confused and Worried

Vox reports that recent policy shifts have led to confusion and uncertainty at the US Food and Drug Administration.

The Wall Street Journal reports that Rep. Tom Price, the pick to lead the Department of Health and Human Services, bought stock in a pharma firm at a special price.

The US immigration ban is already having an effect on US science, the New Scientist says.

Stat News writes that the new executive order on government regulations could affect the 21st Century Cures Act.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.

New Rule

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.


A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.